Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 17, 2008Company plans to launch product immediately
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval for the sale of its TAXUS® Liberte® paclitaxel-eluting...
-
Apr 16, 2008
Boston Scientific Corporation (NYSE: BSX) and CryoCor, Inc. (NASDAQ: CRYO) today announced the signing of a definitive...
-
Apr 15, 2008Emerging technology will potentially enable access to MRI exams for implantable cardiac device patients
Boston Scientific Corporation (NYSE: BSX) and Surgi-Vision, Inc., a privately held company, today announced a licensing and...
-
Apr 14, 2008ACUITY® Steerable lead also receives reimbursement approval; Company plans to launch product immediately
Boston Scientific Corporation (NYSE: BSX) today announced Japanese Ministry of Health, Labor and Welfare (MHLW) approval of its ACUITY® Steerable...
-
Apr 7, 2008
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31,...
-
Apr 7, 2008
Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Timothy Pratt as its new General Counsel. Pratt is a nationally...
-
Apr 2, 2008Judgment entered in favor of Guidant and its former directors/officers
Boston Scientific Corporation (NYSE: BSX) today announced that United States District Judge Sarah Evans Barker, Indianapolis, dismissed...
-
Apr 1, 2008
Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled analysis of patients from its TAXUS IV and TAXUS...
-
Apr 1, 2008Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents
Boston Scientific Corporation (NYSE: BSX) today welcomed favorable outcomes of one- year data from the Company's TAXUS IV and V...
-
Mar 31, 2008At two years, Company's TAXUS® and PROMUS™ Stents demonstrate positive and similar outcomes
Boston Scientific Corporation (NYSE: BSX) today welcomed positive two-year results from Abbott's prospective, randomized (3:1), single...